Search Results - "Collée, J"

Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study by de Jonge, Marthe M, de Kroon, Cornelis D, Jenner, Denise J, Oosting, Jan, de Hullu, Joanne A, Mourits, Marian J E, Gómez Garcia, Encarna B, Ausems, Margreet G E M, Margriet Collée, J, van Engelen, Klaartje, van de Beek, Irma, Smit, Vincent T H B M, Rookus, Matti A, de Bock, Geertruida H, van Leeuwen, Flora E, Bosse, Tjalling, Dekkers, Olaf M, van Asperen, Christi J

“…Endometrial cancer (EC) risk in BReast CAncer gene 1/2 (BRCA1/2) mutation carriers is uncertain; therefore, we assessed this in a large Dutch nationwide cohort…”
Get full text

Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis by Heemskerk-Gerritsen, B.A.M., Menke-Pluijmers, M.B.E., Jager, A., Tilanus-Linthorst, M.M.A., Koppert, L.B., Obdeijn, I.M.A., van Deurzen, C.H.M., Collée, J.M., Seynaeve, C., Hooning, M.J.

“…To prospectively assess the efficacy of bilateral risk-reducing mastectomy (BRRM) when compared with surveillance on breast cancer (BC) risk and mortality in…”
Get full text

EP13.34: Effectiveness of third trimester ultrasound screening in the prediction of small‐for‐gestational‐age neonates: a retrospective cohort study by Collée, J., Noel, L., Henry, L., Nisolle, M., Chantraine, F.

Get full text

The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families by Schreurs, Maartje A.C., Ramón y Cajal, Teresa, Adank, Muriel A., Collée, J. Margriet, Hollestelle, Antoinette, van Rooij, Jeroen, Schmidt, Marjanka K., Hooning, Maartje J.

“…To determine the changes in surveillance category by adding a polygenic risk score based on 311 breast cancer (BC)-associated variants (PRS311),…”
Get full text

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy by Kriege, M, Hollestelle, A, Jager, A, Huijts, P E A, Berns, E M, Sieuwerts, A M, Meijer-van Gelder, M E, Collée, J M, Devilee, P, Hooning, M J, Martens, J W M, Seynaeve, C

“…Background: We assessed the sensitivity to adjuvant chemotherapy in cell cycle checkpoint kinase 2 ( CHEK2 ) vs non- CHEK2 breast cancer patients by comparing…”
Get full text

Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile by Smid, Marcel, Schmidt, Marjanka K, Prager-van der Smissen, Wendy J C, Ruigrok-Ritstier, Kirsten, Schreurs, Maartje A C, Cornelissen, Sten, Garcia, Aida Marsal, Broeks, Annegien, Timmermans, A Mieke, Trapman-Jansen, Anita M A C, Collée, J Margriet, Adank, Muriel A, Hooning, Maartje J, Martens, John W M, Hollestelle, Antoinette

“…CHEK2 c.1100delC was the first moderate-risk breast cancer (BC) susceptibility allele discovered. Despite several genomic, transcriptomic and functional…”
Get full text

The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families by Schreurs, Maartje A.C., Ramón y Cajal, Teresa, Adank, Muriel A., Collée, J. Margriet, Hollestelle, Antoinette, van Rooij, Jeroen, Schmidt, Marjanka K., Hooning, Maartje J.

“…To determine the changes in surveillance category by adding a polygenic risk score based on 311 breast cancer (BC)-associated variants (PRS311),…”
Get full text

Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families by Schreurs, Maartje A.C., Schmidt, Marjanka K., Hollestelle, Antoinette, Schaapveld, Michael, van Asperen, Christi J., Ausems, Margreet G.E.M., van de Beek, Irma, Broekema, Marjoleine F., Margriet Collée, J., van der Hout, Annemieke H., van Kaam, Kim J.A.F., Komdeur, Fenne L., Mensenkamp, Arjen R., Adank, Muriel A., Hooning, Maartje J., Hogervorst, F.B.L., van Leeuwen, F.E., Adank, M.A., Schmidt, M.K., Stommel-Jenner, D.J., de Groot, R., Vieveen, E., Collée, J.M., Geurts-Giele, W., Heemskerk-Gerritsen, B.A.M., Hooning, M.J., Boere, I.A., van Asperen, C.J., Devilee, P., van der Luijt, R.B., Wevers, M.R., Mensenkamp, A.R., de Hullu, J.A., Ausems, M.G.E.M., Koudijs, M.J., Koole, W., van Engelen, K., Gille, J.J.P., Gómez García, E.B., Blok, M.J., Berger, L.P.V., van der Hout, A.H., de Bock, G.H., Yigit, R., Siesling, S., Verloop, J., Voorham, Q.J.M.

“…Female CHEK2 c.1100delC heterozygotes are eligible for additional breast surveillance because of an increased breast cancer risk. Increased risks for other…”
Get full text

Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations by Brohet, Richard M, Velthuizen, Maria E, Hogervorst, Frans B L, Meijers-Heijboer, Hanne E J, Seynaeve, Caroline, Collée, Margriet J, Verhoef, Senno, Ausems, Margreet G E M, Hoogerbrugge, Nicoline, van Asperen, Christi J, Gómez García, Encarna, Menko, Fred, Oosterwijk, Jan C, Devilee, Peter, van't Veer, Laura J, van Leeuwen, Flora E, Easton, Douglas F, Rookus, Matti A, Antoniou, Antonis C

“…BRCA1 or BRCA2 mutations confer increased risks of breast and ovarian cancer, but risks have been found to vary across studies and populations. We ascertained…”
Get more information

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study by Akdeniz, Delal, van Barele, Mark, Heemskerk-Gerritsen, Bernadette A.M., Steyerberg, Ewout W., Hauptmann, Michael, van de Beek, Irma, van Engelen, Klaartje, Wevers, Marijke R., Gómez García, Encarnacion B., Ausems, Margreet G.E.M., Berger, Lieke P.V., van Asperen, Christi J., Adank, Muriel A., Collée, Margriet J., Stommel-Jenner, Denise J., Jager, Agnes, Schmidt, Marjanka K., Hooning, Maartje J.

“…BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the…”
Get full text

Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers by Stroot, Iris A.S., Bart, Joost, Hollema, Harry, Jalving, Mathilde, Wagner, Marise M., Yigit, Refika, van Doorn, Helena C., de Hullu, Joanne A., Gaarenstroom, Katja N., van Beurden, Marc, van Lonkhuijzen, Luc R.C.W., Slangen, Brigitte F.M., Zweemer, Ronald P., Gómez García, Encarna B., Ausems, Margreet G.E.M., Boere, Ingrid A., van Hest, Liselotte P., Duijkers, Floor A.M., van Asperen, Christi J., Schmidt, Marjanka K., Wevers, Marijke R., Ruijs, Marielle W.G., Devilee, Peter, Collée, J. Margriet, HEBON investigators, de Bock, Geertruida H., Mourits, Marian J.E.

“…The aim of this study was to describe the long-term outcome of asymptomatic BRCA1/2 germline pathogenic variant (GPV) carriers with high-grade serous carcinoma…”
Get full text

Urinary incontinence more than 15 years after premenopausal risk‐reducing salpingo‐oophorectomy: a multicentre cross‐sectional study by Terra, Lara, Heemskerk‐Gerritsen, Bernadette A. M., Beekman, Maarten J., Engelhardt, Ellen, Mourits, Marian J. E., Doorn, Helena C., Hullu, Joanna A., Mom, Constantijne H., Slangen, Brigitte F. M., Gaarenstroom, Katja N., Beurden, Marc, Roeters Van Lennep, Jeanine E., Dorst, Eleonora B. L., Kolk, Lizet E., Collée, J. Margriet, Wevers, Marijke R., Ausems, Margreet G .E. M., Engelen, Klaartje, Beek, Irma, Berger, Lieke P. V., Asperen, Christi J., Gomez Garcia, Encarna B., Maas, Angela H. E. M., Hooning, Maartje J., Steensma, Anneke B., Leeuwen, Flora E.

“…Objective To study the impact of premenopausal risk‐reducing salpingo‐oophorectomy (RRSO), compared with postmenopausal RRSO, on urinary incontinence (UI) ≥10…”
Get full text

Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant by Geurts-Giele, Willemina R R, van Verschuer, Victorien M T, van Deurzen, Carolien H M, van Diest, Paul J, Pedrosa, Rute M S M, Collée, J Margriet, Koppert, Linetta B, Seynaeve, Caroline, Dinjens, Winand N M

“…Female BRCA1/2 mutation carriers affected with breast and/or ovarian cancer may develop new tumor deposits over time. It is of utmost importance to know the…”
Get full text

Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy by Terra, Lara, Beekman, Maarten J., Engelhardt, Ellen G., Heemskerk-Gerritsen, Bernadette A.M., van Beurden, Marc, Roeters van Lennep, Jeanine E., van Doorn, Helena C., de Hullu, Joanne A., Van Dorst, Eleonora B.L., Mom, Constantijne H., Slangen, Brigitte F.M., Gaarenstroom, Katja N., van der Kolk, Lizet E., Collée, J. Margriet, Wevers, Marijke R., Ausems, Margreet G.E.M., Van Engelen, Klaartje, van de Beek, Irma, Berger, Lieke P.V., van Asperen, Christi J., Gomez Garcia, Encarna B., Maas, Angela H.E.M., Hooning, Maartje J., Aaronson, Neil K., Mourits, Marian J.E., van Leeuwen, Flora E.

“…Women with a BRCA1/2 pathogenic variant are advised to undergo premenopausal risk-reducing salpingo-oophorectomy after completion of childbearing, to reduce…”
Get full text

Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers by Pijpe, Anouk, Manders, Peggy, Brohet, Richard M., Collée, J. Margriet, Verhoef, Senno, Vasen, Hans F. A., Hoogerbrugge, Nicoline, van Asperen, Christi J., Dommering, Charlotte, Ausems, Margreet G. E. M., Aalfs, Cora M., Gomez-Garcia, Encarna B., van‘t Veer, Laura J., van Leeuwen, Flora E., Rookus, Matti A.

“…BRCA1/2 mutation carriers have a high lifetime risk of developing breast cancer. Differences in penetrance indicate that this risk may be influenced by…”
Get full text

PTEN in colorectal cancer: a report on two Cowden syndrome patients by Kersseboom, R, Dubbink, HJ, Corver, WE, van Tilburg, AJP, Poley, JW, van Leerdam, ME, Atmodimedjo, PN, van de Laar, IMBH, Collée, JM, Dinjens, WNM, Morreau, H, Wagner, A

“…Kersseboom R, Dubbink HJ, Corver WE, van Tilburg AJP, Poley JW, van Leerdam ME, Atmodimedjo PN, van de Laar IMBH, Collée JM, Dinjens WNM, Morreau H, Wagner A…”
Get full text

Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk by Liu, Jingjing, Prager–van der Smissen, Wendy J. C., Schmidt, Marjanka K., Collée, J. Margriet, Cornelissen, Sten, Lamping, Roy, Nieuwlaat, Anja, Foekens, John A., Hooning, Maartje J., Verhoef, Senno, van den Ouweland, Ans M. W., Hogervorst, Frans B. L., Martens, John W. M., Hollestelle, Antoinette

“…The HOXB13 p.G84E mutation has been firmly established as a prostate cancer susceptibility allele. Although HOXB13 also plays a role in breast tumor…”
Get full text

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers by Kriege, Mieke, Jager, Agnes, Hollestelle, Antoinette, Berns, Els M. J. J., Blom, Jannet, Meijer-van Gelder, Marion E., Sieuwerts, Anieta M., van den Ouweland, Ans, Collée, J. Margriet, Kroep, Judith R., Martens, John W. M., Hooning, Maartje J., Seynaeve, Caroline

“…Purpose The role of CHEK2 in DNA repair by homologous recombination suggests that CHEK2 -associated breast cancer (BC) patients might be more sensitive to…”
Get full text

Erratum to ‘The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families’ [The Breast 73 (2024) 103611] by Schreurs, Maartje A.C., Ramón y Cajal, Teresa, Adank, Muriel A., Collée, J. Margriet, Hollestelle, Antoinette, van Rooij, Jeroen, Schmidt, Marjanka K., Hooning, Maartje J.

Get full text

Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset by Davidson, Aimee L, Michailidou, Kyriaki, Parsons, Michael T, Fortuno, Cristina, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Naven, Marc, Abubakar, Mustapha, Ahearn, Thomas U, Alonso, M Rosario, Andrulis, Irene L, Antoniou, Antonis C, Auvinen, Päivi, Behrens, Sabine, Bermisheva, Marina A, Bogdanova, Natalia V, Bojesen, Stig E, Brüning, Thomas, Byers, Helen J, Camp, Nicola J, Campbell, Archie, Castelao, Jose E, Cessna, Melissa H, Chang-Claude, Jenny, Chanock, Stephen J, Chenevix-Trench, Georgia, Collée, J Margriet, Czene, Kamila, Dörk, Thilo, Eriksson, Mikael, Evans, D Gareth, Fasching, Peter A, Figueroa, Jonine D, Flyger, Henrik, Gago-Dominguez, Manuela, García-Closas, Montserrat, Glendon, Gord, González-Neira, Anna, Grassmann, Felix, Gronwald, Jacek, Guénel, Pascal, Hadjisavvas, Andreas, Haeberle, Lothar, Hall, Per, Hamann, Ute, Hartman, Mikael, Ho, Peh Joo, Hooning, Maartje J, Hoppe, Reiner, Howell, Anthony, Jakubowska, Anna, Khusnutdinova, Elza K, Kristensen, Vessela N, Li, Jingmei, Lim, Joanna, Lindblom, Annika, Liu, Jenny, Lophatananon, Artitaya, Mannermaa, Arto, Mavroudis, Dimitrios A, Mensenkamp, Arjen R, Milne, Roger L, Muir, Kenneth R, Newman, William G, Obi, Nadia, Panayiotidis, Mihalis I, Park, Sue K, Park-Simon, Tjoung-Won, Peterlongo, Paolo, Radice, Paolo, Rashid, Muhammad U, Rhenius, Valerie, Saloustros, Emmanouil, Sawyer, Elinor J, Schmidt, Marjanka K, Seibold, Petra, Shah, Mitul, Southey, Melissa C, Teo, Soo Hwang, Tomlinson, Ian, Torres, Diana, Truong, Thérèse, van de Beek, Irma, van der Hout, Annemieke H, Wendt, Camilla C, Dunning, Alison M, Pharoah, Paul D P, Devilee, Peter, Easton, Douglas F, James, Paul A, Spurdle, Amanda B

“…Co-observation of a gene variant with a pathogenic variant in another gene that explains the disease presentation has been designated as evidence against…”
Get more information